Methylphenidate

Generic Name: Methylphenidate

Brand Names: Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₉NO_₂

CAS Number: 113-45-1

Unique Ingredient Identifier: 207ZZ9QZ49

Background: Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...

Indication: Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy

Associated Therapies: -

Clinical Trials

Precision Care for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder
Depression
Depressive Disorder, Major

Interventions: Other: Care as usual (CAU) plan
Behavioral: Complicated Grief Treatment (CGT)
Drug: Pramipexole
Drug: Methylphenidate
Behavioral: Mindfulness-based Stress Sensitivity Therapy (MBSST)
Drug: Phenelzine

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 150

Registration Number: NCT06580041

Locations: 🇺🇸
Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco, San Francisco, California, United States

Methylphenidate in KBG Syndrome: N-of-1 Series

Phase 4

Not yet recruiting

Conditions: Kbg Syndrome
ADHD - Combined Type

Interventions: Drug: Placebo
Drug: Methylphenidate Hydrochloride

First Posted Date: 2024-06-20

Last Posted Date: 2024-06-20

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 15

Registration Number: NCT06465641

Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.

Not Applicable

Recruiting

Conditions: Attention Deficit Disorder With Hyperactivity
Executive Function Disorder

Interventions: Drug: Concerta
Device: Digital therapeutics

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Lei Lei, MD

Target Recruit Count: 200

Registration Number: NCT06369714

Locations: 🇨🇳
Changzheng Hospital, Naval Medical University, Shanghai, Shanghai, China
🇨🇳
Changhai Hospital, Naval Medical University, Shanghai, Shanghai, China

Psilocybin in Chronic Low Back Pain and Depression

Phase 1

Recruiting

Conditions: Chronic Low-back Pain
Depression

Interventions: Drug: Psilocybin
Drug: Methylphenidate

First Posted Date: 2024-04-09

Last Posted Date: 2024-10-26

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 40

Registration Number: NCT06355414

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: 3,4 Methylenedioxymethamphetamine
Drug: Methylphenidate
Drug: Psilocybin

First Posted Date: 2023-10-13

Last Posted Date: 2023-12-07

Lead Sponsor: University of Zurich

Target Recruit Count: 120

Registration Number: NCT06081179

Locations: 🇨🇭
Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland

Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD

Phase 4

Withdrawn

Conditions: ADHD

Interventions: Drug: Methylphenidate
Drug: Placebo

First Posted Date: 2023-10-11

Last Posted Date: 2024-03-15

Lead Sponsor: Johns Hopkins University

Registration Number: NCT06077669

Locations: 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

Recruiting

Conditions: Methylphenidate
Metabolomics

Interventions: Drug: methylphenidate

First Posted Date: 2023-10-10

Last Posted Date: 2024-03-26

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 160

Registration Number: NCT06073470

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Targeting Drug Memories With Methylphenidate

Early Phase 1

Recruiting

Conditions: Substance Use Disorder
Cocaine Use Disorder

Interventions: Drug: Methylphenidate
Behavioral: Memory reconsolidation
Drug: Placebo

First Posted Date: 2023-08-07

Last Posted Date: 2024-06-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 50

Registration Number: NCT05978167

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes

Phase 2

Recruiting

Conditions: Attention Deficit Disorder with Hyperactivity
Diabetes Mellitus, Type 1

Interventions: Behavioral: parental training in behavior management
Drug: Methylphenidate
Drug: Lisdexamfetamine

First Posted Date: 2023-07-24

Last Posted Date: 2024-11-28

Lead Sponsor: Medical University of Lodz

Target Recruit Count: 150

Registration Number: NCT05957055

Locations: 🇵🇱
Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz, Łódź, Łódzkie, Poland

Benefits of ADHD Treatment in Detained People

Phase 3

Recruiting

Conditions: ADHD

Interventions: Drug: Placebo
Drug: Concerta

First Posted Date: 2023-05-06

Last Posted Date: 2024-10-10

Lead Sponsor: Stéphanie Baggio

Target Recruit Count: 150

Registration Number: NCT05842330

Locations: 🇨🇭
Geneva University Hospitals, Geneva, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy